RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. RECEIVES AND APPEALS NASDAQ DELISTING NOTICE

RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. RECEIVES AND APPEALS NASDAQ DELISTING NOTICE

RAIN Enhancement Technologies Holdco, Inc. (Nasdaq: RAIN) (the "Company") announced today that it received a notice (the "Notice") on August 19, 2025 from the Listing Qualifications Staff ("Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has not regained compliance with Nasdaq Listing Rule 5450(b)(2)(A), requiring the Company to maintain a market value of listed securities of at least $50 million, and Nasdaq Listing Rule 5450(b)(2)(B), requiring the Company to maintain a market value of publicly held shares of at least $15 million. The Notice provides that the Company has until 4:00 p.m. Eastern Time on August 26, 2025 to appeal the Staff's delisting determination.

Pursuant to the Notice, unless the Company timely requests a hearing from the Nasdaq Hearing Panel (the "Panel"), the Company's securities will be subject to suspension and delisting from the Nasdaq Global Market at the opening of business on August 28, 2025. The Company submitted its timely request for a hearing before the Panel on August 21, 2025 to request additional time to regain compliance with Nasdaq listing rules. The Company expects that its hearing request will result in a stay of any suspension or delisting action pending the hearing. At the hearing, the Company intends to present its plan to achieve compliance with all applicable listing criteria; however, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to achieve compliance within any period of time that may be granted by the Panel. The Company is considering all options available to it to regain compliance with all applicable listing rules.

About Rain Enhancement Technologies Holdco, Inc.

The Company was founded to provide the world with reliable access to water, one of life's most important resources. To achieve this mission, the Company aims to develop, manufacture and commercialize ionization rainfall generation technology. This weather modification technology seeks to provide the world with reliable access to water, and transform business, society and the planet for the better.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained in this press release consists of forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words such as "would," "will," "expects," "intends," and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Panel will grant the Company's request for continued listing, or any relief from delisting, or that the Company will be able to achieve compliance with Nasdaq listing rules within any period of time that may be granted by the Panel. Additional factors that could cause actual results to differ from the forward-looking statements herein include potential adverse effects on the Company's business related to the disclosures made in this Current Report on Form 8-K or the exhibit hereto, or the initiation of new legal proceedings, volatility of the Company's stock price, and the other risk factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and the Company's other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date of this press release and the Company undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.

Contacts:

Investors

RainwaterTechIR@icrinc.com

Media

RainwaterTechPR@icrinc.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

RAIN
The Conversation (0)
Rain Therapeutics Inc.

Rain Therapeutics Inc.

Rain Therapeutics Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Angkor Resources Advances Seismic Program With Enercam's Oil & Gas Block VIII, Cambodia

Angkor Resources Advances Seismic Program With Enercam's Oil & Gas Block VIII, Cambodia

(TheNewswire)

GRANDE PRAIRIE, ALBERTA - August 14, 2025 TheNewswire - Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) ("ANGKOR" OR "THE COMPANY") announces its subsidiary, EnerCam Resources Co. Ltd. (Cambodia) ("EnerCam") is well underway to complete Cambodia's onshore EnviroVibe oil and gas 2-D seismic for Block VIII ("Project").

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
American Salars Starts Sampling at 100% Owned Brazilian LCT Pegmatite Project, with Past Samples Hitting 3.72% Li2o and Significant Ree Values

American Salars Starts Sampling at 100% Owned Brazilian LCT Pegmatite Project, with Past Samples Hitting 3.72% Li2o and Significant Ree Values

(TheNewswire)

VANCOUVER, BC TheNewswire - MAY 7 th 2025 American Salars Lithium Inc. ("AMERICAN SALARS" OR THE "COMPANY") (CSE: USLI, OTC: USLIF, FWB: Z3P, WKN: A3E2NY ) announces that it has commenced a Phase 2 sampling program on its 100% owned, highly prospective 18,083 Hectares (180 sq km) Hardrock LCT ("Lithium-Cesium-Tantalum") Pegmatite Project including Rare Earth Elements ("REEs") and Critical Minerals (the "Jaguaribe Project ").

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Element79 Gold Corp. Provides Chachas Community update

Element79 Gold Corp. Provides Chachas Community update

(TheNewswire)

Vancouver, British Columbia TheNewswire - March 28, 2024 Element79 Gold Corp. (CSE: ELEM | FSE: 7YS0 | OTC: ELMGF) is pleased to provide an update on the latest Chachas community engagement and ongoing efforts for its Minas Lucero Project in Arequipa, Peru.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Element79 Gold Corp Provides Update on Social Management and Community Engagement for the Minas Lucero Project

Element79 Gold Corp Provides Update on Social Management and Community Engagement for the Minas Lucero Project

(TheNewswire)

Vancouver, British Columbia TheNewswire - March 11, 2024 Element79 Gold Corp. (CSE: ELEM | FSE: 7YS0 | OTC: ELMGF) is pleased to provide an update on the latest social management initiatives, community engagement and ongoing efforts for its Minas Lucero Project in the Arequipa region of Peru.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
  MOAB Minerals

$2M Placement Completed to Advance Drilling at Tanzanian Projects

Moab Minerals Limited (ASX: MOM) (Moab or the Company) is pleased to announce it has secured binding commitments from sophisticated and professional investors of the Company to raise $2m (before costs) via a placement of ordinary shares at an issue price of $0.003 per share (Placement).

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News

×